SaTX-1 / StarkAge Therap - LARVOL DELTA

Dipeptidyl peptidase 4 (DPP4) as a new senescence-associated target to eliminate cancer cells (ESMO-TAT 2025) - "Exploiting the targeting of senescent cells in cancer based on selected biomarkers such as DPP4 constitutes a new therapeutic avenue to counteract tumor dormancy, recurrences, and resistance to conventional chemo/radiotherapies. Our results highlight that STX-1 is a first-in-class ADC suitable for the therapeutic targeting of several cancer indications alone and using synergistic combinations."

Oncology • DPP4

STX-1, a potent first-in-class ADC directed against DPP4 (CD26) as a biomarker of senescent tumor cells (AACR 2024) - "This IgG1/k mAb has potent in vitro activities on DPP4+ cells : i) in a bleomycin-induced senescent fibroblasts model; ii) on DPP4-expressing and chemotherapy- or radiotherapy-induced senescent human tumor cell lines with overexpression of DPP4; iii) binding of the mAb to its target results in its internalization into the endolysosomal compartment of cells. Further studies will include optimization of the best STX-1 formulation, NHP studies and GMP scale-up with planned IND submission expected in Q3-2024. Exploiting the targeting of senescent cells in cancer based on selected biomarkers such as DPP4 constitutes a new therapeutic avenue to counteract tumor dormancy, recurrences and resistance to conventional chemo/radiotherapies."

Biomarker • Tumor cell • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • DPP4